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• Breast cancer is the 2nd cause of death and the 1st diagnosed neoplasia among women in developed 
countries. Its incidence is increasing, whereas mortality is decreasing. 
• Breast cancer diversity urges the application of personalized medicine. 
Tamoxifen is an efficient treatment for early stages of breast cancer, with low risk of recurrence. It 
blocks the action of the estrogen, therefore suitable for tumors with specific estrogen receptors. (1) 
 
THE ROLE OF CYP2D6 POLYMORPHISMS IN BREAST CANCER PATIENTS 
DESCRIPTION 
• Treatment choice depends on risk of recurrence, clinical stage and predictive factors. 
• Drugs present a wide range of pharmacokinetics, pharmacodynamics, toxicity and tolerance in 
individuals that may be explained by the presence of GENETIC POLYMORPHISIMS. 
 
OBJECTIVE 
TAMOXIFEN 
The aim of this review is to describe the pharmacogenetics and response of breast cancer patients to 
tamoxifen, the role that CYP2D6 has on it and whether it can be used as a reliable biomarker. 
GENES related to Tamoxifen 
EFFICACY: 
•CYP3A4 
•SULTIAI 
•CYP2C19 
•CYP3A4/5 
•CYP2B6  
•CYP2C9 
•CYP2D6 
•Among others 
 Tamoxifen activity is mediated 
by cytochrome P450 2D6 
(CYP2D6) (2) 
 
Genetic polymorphisms may affect 
tamoxifen concentrations, its 
metabolites and the effectiveness 
of the drug. 
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CYTOCHROME P450 2D6 (CYP2D6) 
• CYP2D6 is a cytochrome P450 expressed in the liver, whose lack of activity leads to the formation of 
inactive truncated proteins.  
88 allelic variants of 
CYP2D6 have been 
described, which can be 
classified in four different 
PHENOTYPIC GROUPS (2) 
• The Roche DNA microarray-based pharmacogenetics test for CYP2D6 and CYP2C19 variants (approved by FDA), called AmplyChip CYP450 test, allows the identification of 27 of the 
different CYP2D6 variants. But it is not recommended applying the CYP2D6 test yet. (7) 
• The Hap Map Project, has the aim to determine the haplotype of four different population groups, in order to identify the candidate genes with the correct haplotype labeling SNPs. (4) 
STATE OF THE ART 
• There is an association between CYP2D6 genetic variants and tamoxifen outcomes in breast cancer patients, having CYP2D6 a gene-dose effect. 
• Best outcomes correspond to ultraextensive and extensive metabolizers, while the worst to intermediate and poor metabolizers. 
• Tamoxifen metabolism may involve different genes, pathways, and combinations of them. 
CONCLUSIONS REFERENCES 
• Worst outcomes after tamoxifen treatment: CYP2D6 alleles *4, *5, *10, and *41. (3) 
• Recurrence rates: EM 14.9%, E/I M 20.9%, and PM 29.0%. (4) 
• Mortality rates: 16.7% for EM, 18.0% for E/I M, and 22.8% for PM. (4) 
•There is an association between PM CYP2D6 alleles and the worst outcomes of disease-free survival. (4) 
DISTRIBUTION of 
the individuals 
can be different 
according the 
ethnicity they 
belong to 
OTHER INVOLVED ENZYMES 
More trials are needed before CYP2D6 can be used as a reliable biomarker of tamoxifen effectiveness in breast cancer patients.  
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Figure 4. Kaplan-Meier of: time to recurrence, event-free survival and disease-free survival for CYP2D6 EM, EM/IM and PM phenotypes (4) 
 
Figure 5. AmplyChip CYP450 (7) 
Type of metabolizer CYP2D6 Genetic variants 
Ultraextensive metabolizer (UM) CYP2D6 *1xN 
CYP2D6 *2xN 
CYP2D6 *35xN 
CYP2D6 *41xN 
Extensive metabolizer (EM), (wt alleles) CYP2D6 *1 
CYP2D6 *2 
CYP2D6 *35 
Intermediate metabolizer (IM) CYP2D6 *9 
CYP2D6 *10 
CYP2D6 *17 
CYP2D6 *41 
Poor metabolizer (P), (Null alleles) CYP2D6 *3 
CYP2D6 *4 
CYP2D6 *5 
CYP2D6 *6 
CYP2D6 *7 
CYP2D6 *8 
CYP2D6 *11 
Rare variants: *12, *13, *14, *15,  *16, *18, 
*19, *20, *21, *38, *40, *42, *44, *56, *62 
• CYP2C19 *17  better outcomes. (3) 
• SULT1A2*2 and SULT1A2*3  higher 4-hydroxy-tamoxifen and endoxifen plasma levels. (5) 
• CYP3A5 *3/*3 treated with tamoxifen during 2 years  higher risk of recurrence. (6) 
• CYP3A5 *3/*3 treated with tamoxifen during 5 years  increased disease-free survival rate.(6) 
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Figure 1. Most common treatment for breast cancer. 
Figure 2. Degrees of tolerance to breast cancer drugs. 
Table 2. Polymorphisms frequencies among phenotypic groups. 
Table 1. CYP2D6 most common genetic variants classified in phenotypic groups. 
Figure 3 . Tamoxifen metabolism. (1) 
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